Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

<p>Cell line and PDX genetics</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Elizabeth R. Tucker (15053624) (author)
Altres autors:	Irene Jiménez (15053627) (author), Lindi Chen (15053630) (author), Angela Bellini (15053633) (author), Chiara Gorrini (15053636) (author), Elizabeth Calton (15053639) (author), Qiong Gao (15053642) (author), Harvey Che (15053645) (author), Evon Poon (15053648) (author), Yann Jamin (14936271) (author), Barbara Martins Da Costa (15053651) (author), Karen Barker (15053654) (author), Sumana Shrestha (15053657) (author), J. Ciaran Hutchinson (15053660) (author), Simran Dhariwal (15053663) (author), Angharad Goodman (15053666) (author), Elaine Del Nery (15053669) (author), Pierre Gestraud (15022362) (author), Jaydutt Bhalshankar (15053672) (author), Yasmine Iddir (15053675) (author), Elnaz Saberi-Ansari (15053678) (author), Alexandra Saint-Charles (15053681) (author), Birgit Geoerger (14952291) (author), Maria Eugénia Marques Da Costa (15053684) (author), Cécile Pierre-Eugène (15053687) (author), Isabelle Janoueix-Lerosey (15053690) (author), Didier Decaudin (15053693) (author), Fariba Nemati (15053696) (author), Angel M. Carcaboso (15053699) (author), Didier Surdez (14941221) (author), Olivier Delattre (15053702) (author), Sally L. George (15053705) (author), Louis Chesler (14934315) (author), Deborah A. Tweddle (15053708) (author), Gudrun Schleiermacher (15053711) (author)
Publicat:	2025
Matèries:	Cancer Therapeutic Research and Development Methods and Technology Chemotherapy Combination chemotherapy Pediatric Cancers Preclinical Models Animal models of cancer In vitro models of cancer Xenograft models Small Molecule Agents Kinase inhibitors Translational Research
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
per: Alyssa C. Flint (16676029)
Publicat: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
per: Alyssa C. Flint (16676029)
Publicat: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
per: Anne-Florence Blandin (15056366)
Publicat: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
per: Anne-Florence Blandin (15056366)
Publicat: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
per: Anne-Florence Blandin (15056366)
Publicat: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
per: Anne-Florence Blandin (15056366)
Publicat: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
per: Anne-Florence Blandin (15056366)
Publicat: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
per: Anne-Florence Blandin (15056366)
Publicat: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
per: Anne-Florence Blandin (15056366)
Publicat: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
per: Arun Kanakkanthara (14937731)
Publicat: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
per: Arun Kanakkanthara (14937731)
Publicat: (2025)

Supplementary Table S1 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
per: Ke Peng (15048177)
Publicat: (2025)

Supplementary Table S2 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
per: Ke Peng (15048177)
Publicat: (2025)

Supplementary Table S3 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
per: Ke Peng (15048177)
Publicat: (2025)

Supplementary Table S4 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
per: Ke Peng (15048177)
Publicat: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
per: Katie E. Hebron (15046889)
Publicat: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
per: Katie E. Hebron (15046889)
Publicat: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
per: Katie E. Hebron (15046889)
Publicat: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
per: Katie E. Hebron (15046889)
Publicat: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
per: Katie E. Hebron (15046889)
Publicat: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
per: Katie E. Hebron (15046889)
Publicat: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
per: Katie E. Hebron (15046889)
Publicat: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
per: Zev A. Wainberg (15047031)
Publicat: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
per: Sheheryar Kabraji (15050565)
Publicat: (2025)

Supplementary Movie S1 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Movie S2 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Movie S3 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Movie S4 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Movie S5 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Movie S6 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Movie S7 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Movie S8 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Movie S9 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
per: Jesse C. Patterson (14962862)
Publicat: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
per: Caleb N. Seavey (15056489)
Publicat: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
per: Caleb N. Seavey (15056489)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_63bj5g0u2vns83cld5lrd6vhnb